Clinical Trials of Drugs and Vaccines Among the Desperately Poor in Poor Nations: Ethical Challenges and Ethical Solutions
Author:
- 1 November 2010
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 88 (5) , 583-584
Abstract
Clinical research has been expanding into poor nations in recent years. In doing research in such settings, the response to challenges arising due to the vulnerability and resultant potential exploitation of very poor subject populations is heightened awareness of the need for adequate local oversight and regulation. More regulation, however, often is difficult to implement and may not be practical. The provision of benefit at the conclusion of clinical trials in poor nations or for poor people is a better response to the moral challenge of exploitation.Keywords
This publication has 4 references indexed in Scilit:
- Why Adopt a Maximin Theory of Exploitation?The American Journal of Bioethics, 2010
- Unlicensed pandemic influenza A H1N1 vaccinesThe Lancet, 2010
- Corporate Responsibilities for Access to MedicinesJournal of Business Ethics, 2008
- Trends in the globalization of clinical trialsNature Reviews Drug Discovery, 2008